Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Total Debt

Short-term and long-term borrowings combined.

Sera Prognostics, Inc.NASDAQ: SERA

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 341.0% from a year ago

Total debt stood at $2.51M at the end of Q1 FY2026, up 341.0% from a year earlier and up 7.1% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.

Context

  • Total debt amounted to 2.7% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +341.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.51M+7.1% QoQ
Last fiscal yearDec 2025
$2.34M+178.5% YoY
Year agoMar 2025
$568K+341.0% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+341.0%——
1 year+178.5%——
3-year CAGR-6.2%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
2.34M USD
Year-over-year change
+178.5%
4-year CAGR
+106.8%

Total Debt vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +341.0% is the highest of 8, against a peer median of -14.9%.
  • Total debt amounts to 2.7% of total assets for SERA, versus a peer median of 5.9%.
SERA Competitors
Total Debt for SERA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
APYXApyx Medical CorporationMar 2026$39.46M USD+1.4%+267.0%62.6%
LUCDLucid Diagnostics Inc.Mar 2026$26.8M USD-24.0%+134.6%78.6%
RPIDRapid Micro Biosystems, Inc.Mar 2026$23.71M USD+303.5%+44.2%38.0%
SRZNSurrozen, Inc.Mar 2026$6.78M USD-14.9%+5.8%5.6%
SERASera Prognostics, Inc.Mar 2026$2.51M USD+341.0%-6.2%2.7%
ONCYOncolytics Biotech Inc.Mar 2026CA$508K CAD-49.2%+27.5%6.2%
CGTXCognition Therapeutics, Inc.Mar 2026$465K USD-26.8%-24.4%1.3%
HURATuHURA Biosciences, Inc.Mar 2026$456.93K USD+177.6%+71.7%1.5%
STSSSkyAI, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding SERA) —-14.9%+44.2%5.9%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents58.93M29.88M3.88M4.04M3.94M
Short-term Investments46.18M52.83M45.2M42.19M35.26M
Net Receivables3.14M6.11M11.47M34K12K
Inventory00000
Other Current Assets1.99M1.31M795K19K1.56M
Total Current Assets110.25M90.13M61.34M47.6M40.77M
Property, Plant & Equipment (Net)1.77M3.06M3.18M1.85M3.55M
Goodwill00000
Intangible Assets0001.03M910K
Long-term Investments34.85M21.33M30.84M21.97M56.58M
Tax Assets00000
Other Non-current Assets157K1.82M77K124K123K
Total Non-current Assets36.78M26.2M34.1M24.98M61.16M
Total Assets147.03M116.33M95.44M72.58M101.93M
Account Payables1.2M1.55M1.05M1.97M862K
Short-term Debt00000
Tax Payables00000
Deferred Revenue3.12M9.08M20.24M20.22M20.32M
Other Current Liabilities3.56M1.07M926K20.52M3.01M
Total Current Liabilities8.41M15.54M24.44M24.77M24.19M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities54K1.85M840K2K2.34M
Total Liabilities8.47M17.39M25.28M24.77M26.53M
Common Stock3K3K3K3K4K
Retained Earnings(166.47M)(210.65M)(246.9M)(279.79M)(311.72M)
Accumulated OCI(183K)(981K)(15K)60K262K
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity138.56M98.94M70.16M47.8M75.41M
Total Debt128K2.83M1.86M840K2.34M
Net Debt(58.8M)(27.05M)(2.02M)(3.2M)(1.61M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.